| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TFX Stock Overview
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
Teleflex Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$325.75 |
| 52 Week High | US$449.38 |
| 52 Week Low | US$289.00 |
| Beta | 1.11 |
| 1 Month Change | 1.32% |
| 3 Month Change | -9.48% |
| 1 Year Change | -16.12% |
| 3 Year Change | 26.30% |
| 5 Year Change | 96.95% |
| Change since IPO | 3,039.76% |
Recent News & Updates
Is Now An Opportune Moment To Examine Teleflex Incorporated (NYSE:TFX)?
Today we're going to take a look at the well-established Teleflex Incorporated ( NYSE:TFX ). The company's stock saw a...
Is Teleflex (NYSE:TFX) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Teleflex Is Now Trading At Fair Value
About two years ago, I wrote a very bearish article on Teleflex due to a high valuation. Since that time, Teleflex stock has produced almost zero returns while the S&P 500 has returned over +60%. In this article, I revisit Teleflex stock to see where the valuation currently stands.
Shareholder Returns
| TFX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.9% | -1.2% | -0.5% |
| 1Y | -16.1% | 3.8% | 13.7% |
Return vs Industry: TFX underperformed the US Medical Equipment industry which returned 3.8% over the past year.
Return vs Market: TFX underperformed the US Market which returned 13.7% over the past year.
Price Volatility
| TFX volatility | |
|---|---|
| TFX Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: TFX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: TFX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 14,000 | Liam Kelly | https://www.teleflex.com |
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices.
Teleflex Fundamentals Summary
| TFX fundamental statistics | |
|---|---|
| Market Cap | US$15.26b |
| Earnings (TTM) | US$434.26m |
| Revenue (TTM) | US$2.76b |
35.1x
P/E Ratio5.5x
P/S RatioIs TFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TFX income statement (TTM) | |
|---|---|
| Revenue | US$2.76b |
| Cost of Revenue | US$1.25b |
| Gross Profit | US$1.51b |
| Expenses | US$1.08b |
| Earnings | US$434.26m |
Last Reported Earnings
Sep 26, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.27 |
| Gross Margin | 54.86% |
| Net Profit Margin | 15.74% |
| Debt/Equity Ratio | 56.3% |
How did TFX perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield15%
Payout RatioValuation
Is Teleflex undervalued compared to its fair value and its price relative to the market?
26.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TFX ($325.75) is trading below our estimate of fair value ($441.91)
Significantly Below Fair Value: TFX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TFX is good value based on its PE Ratio (35.1x) compared to the US Medical Equipment industry average (47.8x).
PE vs Market: TFX is poor value based on its PE Ratio (35.1x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: TFX is poor value based on its PEG Ratio (5.9x)
Price to Book Ratio
PB vs Industry: TFX is overvalued based on its PB Ratio (4.2x) compared to the US Medical Equipment industry average (3.5x).
Future Growth
How is Teleflex forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
5.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TFX's forecast earnings growth (5.9% per year) is above the savings rate (2%).
Earnings vs Market: TFX's earnings (5.9% per year) are forecast to grow slower than the US market (13% per year).
High Growth Earnings: TFX's earnings are forecast to grow, but not significantly.
Revenue vs Market: TFX's revenue (5.8% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: TFX's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TFX's Return on Equity is forecast to be low in 3 years time (17.2%).
Past Performance
How has Teleflex performed over the past 5 years?
17.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TFX has high quality earnings.
Growing Profit Margin: TFX's current net profit margins (15.7%) are higher than last year (14.7%).
Past Earnings Growth Analysis
Earnings Trend: TFX's earnings have grown by 17.1% per year over the past 5 years.
Accelerating Growth: TFX's earnings growth over the past year (17.9%) exceeds its 5-year average (17.1% per year).
Earnings vs Industry: TFX earnings growth over the past year (17.9%) underperformed the Medical Equipment industry 51.2%.
Return on Equity
High ROE: TFX's Return on Equity (11.9%) is considered low.
Financial Health
How is Teleflex's financial position?
Financial Position Analysis
Short Term Liabilities: TFX's short term assets ($1.5B) exceed its short term liabilities ($562.2M).
Long Term Liabilities: TFX's short term assets ($1.5B) do not cover its long term liabilities ($2.8B).
Debt to Equity History and Analysis
Debt Level: TFX's net debt to equity ratio (42.5%) is considered high.
Reducing Debt: TFX's debt to equity ratio has increased from 47.6% to 56.3% over the past 5 years.
Debt Coverage: TFX's debt is well covered by operating cash flow (31.3%).
Interest Coverage: TFX's interest payments on its debt are well covered by EBIT (8.9x coverage).
Balance Sheet
Dividend
What is Teleflex current dividend yield, its reliability and sustainability?
0.42%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TFX's dividend (0.42%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.32%).
High Dividend: TFX's dividend (0.42%) is low compared to the top 25% of dividend payers in the US market (3.44%).
Stability and Growth of Payments
Stable Dividend: TFX is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: TFX is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TFX is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TFX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.2yrs
Average management tenure
CEO
Liam Kelly (54 yo)
5.67yrs
Tenure
US$6,328,349
Compensation
Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. He serves as Director of Colfax Corporation since January 1,...
CEO Compensation Analysis
Compensation vs Market: Liam's total compensation ($USD6.33M) is below average for companies of similar size in the US market ($USD11.18M).
Compensation vs Earnings: Liam's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: TFX's management team is seasoned and experienced (5.2 years average tenure).
Board Members
Experienced Board: TFX's board of directors are considered experienced (5.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TFX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Teleflex Incorporated's employee growth, exchange listings and data sources
Key Information
- Name: Teleflex Incorporated
- Ticker: TFX
- Exchange: NYSE
- Founded: 1943
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$15.260b
- Shares outstanding: 46.84m
- Website: https://www.teleflex.com
Number of Employees
Location
- Teleflex Incorporated
- 550 East Swedesford Road
- Suite 400
- Wayne
- Pennsylvania
- 19087-1603
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/16 23:25 |
| End of Day Share Price | 2022/01/14 00:00 |
| Earnings | 2021/09/26 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.